Equifax Inc. (EFX)

Equifax's stock has rallied hard into November, trading at $188.41 after a 27.88% gain over the past month, and it now sits above its 20-day, 50-day and 200-day averages. The move follows a quarter in which adjusted earnings of $2.26 per share beat the $2.20 estimate, and the stock rose 11.33% in the first session after that October 20, 2026 report. The rating picture has turned more mixed since: RBC Capital downgraded the stock to Sector Perform on October 26, 2026, even as Argus Research upgraded it to Buy on October 22, 2026. For investors, the question is whether earnings momentum can hold the stock above its recent gains while analysts disagree on the next leg.

Equifax reported adjusted EPS of $2.26 on October 20, 2026, ahead of the $2.20 analyst estimate, a beat of 2.73%. The stock rose 11.33% in the first trading session after that report, the largest reaction in the five-report record. The gain carried into the broader month, with the stock up 27.88% over the past month, and the price is now 13.37% above its 50-day SMA and 7.04% above its 200-day SMA. That is a strong short-term run, but the one-year figure is still negative at 11.40%, so the stock has only recently recovered lost ground.

Ratings have moved in both directions in recent weeks. Argus Research upgraded the stock to Buy from Hold on October 22, 2026, while RBC Capital downgraded it to Sector Perform from Outperform on October 26, 2026. Stifel and Needham kept Buy ratings on October 21, 2026, BMO Capital kept its Market Perform rating the same day, and Mizuho kept its Outperform rating on October 19, 2026. Of 24 analysts with a current rating, 17 rate the stock buy or strong buy and 7 hold it, with none at sell. Three months ago, 16 of 24 rated it buy, so the buy count has risen since then.

At a trailing P/E of 30.49, Equifax trades 10.3% below the sector median of 34.0, which the peer comparison describes as broadly in line with peers. The price-to-sales ratio of 3.36 sits 16.1% below the sector median of 4.0. Profitability is solid rather than exceptional, with a 10.80% net margin, a 20.99% operating margin and a 15.44% return on equity, which is below the sector median of 17.8%. Debt-to-equity stands at 1.13. The earnings record is consistent: all five of the last reports beat the EPS estimate, but the share price fell in the first session after three of them, so beats alone have not guaranteed gains.

Insiders sold $58.5M of stock across recent filings over the last 18 months and bought $465K of shares in one open-market purchase over the same period. Insider sales are often planned in advance or made to cover tax on vesting shares, so they carry less signal than an open-market purchase, and the sales volume is large relative to the single buy.

The base case is that Equifax keeps growing earnings in line with what analysts expect, with fiscal 2026 EPS estimated at $8.51 and 2027 at $9.54, and that the stock continues to trade with its trend intact while the 20-day EMA at $180.44 acts as the first check on the rally. Analysts' 12-month targets run from $155.00 to $245.00, with a median of $203.00, which is 7.7% above the price. The case improves if revenue growth, which was 10.61% in the latest quarter, keeps pace with the 11.7% sector median and if further beats follow the pattern of the last five reports. The case weakens if the stock loses the 200-day SMA at $176.02 or if more analysts move to the sidelines after RBC's downgrade. Simulations based on past volatility are not forecasts, and the stock's 3.03% typical daily move means a sharp swing in either direction remains ordinary for this shares.

Support sits first at the 20-day EMA of $180.44, the nearest level below the price, where the recent rally would be tested. Below that is the 200-day SMA at $176.02, which the stock has been trading above, and then the 50-day SMA at $166.18, which marks where the stock stood before the latest run. The 52-week low of $137.01 is the furthest floor. Resistance sits at the 52-week high of $228.67, the only level above the price. The analysts' median target of $203.00 is not a chart level but sits between the price and that high.